Phase 3 Myeloid Clinical Trials
46 recruitingPhase 3
What is a Phase 3 trial?
Phase 3 trials compare the new treatment against the current standard of care in large groups, often hundreds to thousands of participants. Successful Phase 3 results are typically required for regulatory approval.
Showing 1–20 of 46 trials
Recruiting
Phase 2Phase 3
A Multi-phase Study of ASTX030 (Azacitidine and Cedazuridine) in Myeloid Neoplasm Alone or in Combination With Venetoclax in AML (AZTOUND Study)
Acute Myeloid LeukemiaMyelodysplastic SyndromesChronic Myelomonocytic Leukemia+1 more
Taiho Oncology, Inc.316 enrolled71 locationsNCT04256317
Recruiting
Phase 2Phase 3
L-Annamycin for Injection in Combination With Cytarabine Injection as Second Line Therapy for Remission Induction in Adult Subjects With Refractory/Relapsed AML
Acute Myeloid Leukaemia (AML)
Moleculin Biotech, Inc.312 enrolled25 locationsNCT06788756
Recruiting
Phase 3
Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
PedAL BCU, LLC130 enrolled89 locationsNCT05183035
Recruiting
Phase 3
Mocravimod as Adjunctive and Maintenance Treatment in AML Patients Undergoing Allo-HCT
Adult Acute Myeloid Leukemia
Priothera SAS366 enrolled108 locationsNCT05429632
Recruiting
Phase 3
Phase III Study of Induction and Consolidation Chemotherapy With Venetoclax in Patients With Newly Diagnosed AML or MDS-EB-2
Acute Myeloid Leukemia
University of Ulm650 enrolled91 locationsNCT04628026
Recruiting
Phase 3
A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)
Leukemia, Myeloid, Acute
Janssen Research & Development, LLC600 enrolled239 locationsNCT06852222
Recruiting
Phase 3
Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML
Acute Myeloid Leukemia (AML)
Kura Oncology, Inc.1,300 enrolled39 locationsNCT07007312
Recruiting
Phase 3
IMPACT-AML: A Randomized Pragmatic Clinical Trial for Relapsed or Refractory Acute Myeloid Leukemia.
Acute Myeloid LeukemiaRelapse/Recurrence
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS339 enrolled47 locationsNCT06713837
Recruiting
Phase 3
Bleximenib in Combination With Standard Induction and Consolidation Therapy Followed by Maintenance for Treatment of Patients With Acute Myeloid Leukemia (AML)
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland875 enrolled8 locationsNCT07223814
Recruiting
Phase 3
Study of Revumenib in Combination With Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia (AML) With a NPM1 Mutation
Acute Myeloid Leukemias
Syndax Pharmaceuticals468 enrolled9 locationsNCT07211958
Recruiting
Phase 3
MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib
Acute Myeloid Leukemia (AML)Maintenance TherapyAllogeneic Hematopoietic Cell Transplantation (HCT)+3 more
The First Affiliated Hospital of Soochow University594 enrolled2 locationsNCT07463651
Recruiting
Phase 3
Fludarabine Plus Melphalan Versus Addition of Venetoclax to Fludarabine/Melphalan Conditioning Regimen for Allogeneic Hematopoietic Stem Cell Transplantation in AML/MDS Patients Aged > 50 Years: a Multicenter, Randomized, Phase 3 Trial
VenentoclaxALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATIONMyeloid Malignancies+3 more
First Affiliated Hospital of Zhejiang University186 enrolled18 locationsNCT07396480
Recruiting
Phase 3
A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations
Acute Myeloid Leukemia
Children's Oncology Group1,186 enrolled205 locationsNCT04293562
Recruiting
Phase 2Phase 3
Venetoclax to Improve Outcomes of Fractionated Busulfan Regimen in Patients With High-Risk AML and MDS
Acute Myeloid LeukemiaMyelodysplastic SyndromeChronic Myelomonocytic Leukemia
M.D. Anderson Cancer Center324 enrolled1 locationNCT04708054
Recruiting
Phase 2Phase 3
Co-infusion of Treg-enriched Donor Lymphocytes With CD3-depleted Hematopoietic Stem Cell Graft to Prevent Graft-versus Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation Among Children With Hematologic Malignancies
Acute Myeloid Leukemia, RelapsedAcute Lymphoblastic Leukemia, High RiskAcute Myeloid Leukemia, High Risk+1 more
Federal Research Institute of Pediatric Hematology, Oncology and Immunology64 enrolled1 locationNCT07366801
Recruiting
Phase 3
A Pivotal Study of APG-2575 (Lisaftoclax) Combined With Azacitidine in the Treatment of Acute Myeloid Leukemia
Acute Myeloid Leukemia
Ascentage Pharma Group Inc.486 enrolled6 locationsNCT06389292
Not Yet Recruiting
Phase 3
ALLG AMLM29 CAVIAT-R (Chemotherapy and Venetoclax in Acute Myeloid Leukaemia (AML) Trial- Randomised): a multicentre phase III trial investigating venetoclax plus intensive chemotherapy for newly diagnosed AML
Acute Myeloid Leukaemia
Australasian Leukaemia and Lymphoma Group390 enrolled1 locationACTRN12625001003460
Recruiting
Phase 3
Ivosidenib and Azacitidine With or Without Venetoclax in Adult Patients With Newly Diagnosed IDH1-Mutated AML or MDS/AML Considered Ineligible for Intensive Chemotherapy
Acute Myeloid Leukemia
Stichting Hemato-Oncologie voor Volwassenen Nederland227 enrolled119 locationsNCT07075016
Recruiting
Phase 3
A Study to Evaluate HMPL-306 in Patients With IDH1or IDH2-mutated Acute Myeloid Leukemia
Acute Myeloid Leukemia
Hutchmed316 enrolled53 locationsNCT06387069
Recruiting
Phase 3
Effectiveness of Medium-Dose Cytarabine Combined With Venetoclax for Consolidation Therapy in Elderly Patients With Intermediate to High-Risk Acute Myeloid Leukemia
ElderlyAcute Myeloid Leukemia (AML)
Yehui Tan68 enrolled1 locationNCT06990321